Wuhan YZY Biopharma Plans Major Connected Share Issue Requiring Whitewash WaiverTip Ranks·Sep 9, 2026 at 02:08 PM024960.00%
Wuhan YZY Biopharma Halts Hong Kong Trading Ahead of Takeover-Related AnnouncementTip Ranks·Aug 31, 2026 at 01:07 AM024960.00%
STOCKS | Hong Kong Exchange Lists Suspended CompaniesCoinLive·Aug 31, 2026 at 01:05 AM003180.00%01124+0.77%
Wuhan YZY Biopharma H1 FY26 net loss narrows to RMB 6.26 million; revenue falls 10.87% to RMB 33.14 millionPUBT·Aug 28, 2026 at 08:46 AM024960.00%
Wuhan YZY Biopharma schedules board meeting to review interim resultsPUBT·Aug 18, 2026 at 08:41 AM024960.00%
"Performance" YZYBIO's annual loss narrowed to RMB 84.732 millionAASTOCKS·Mar 30, 2026 at 02:52 AM024960.00%
Wuhan YZY Biopharma (SEHK:2496) Loss Deepens In 1H 2025 Challenging Improving Loss Trend NarrativeSimplywall·Mar 29, 2026 at 09:40 AM024960.00%
Hong Kong Stock Movement: YZYBIO-B fell by 12.28%, with clear capital flow and increased volatility attracting market attentionHK Stock Alerts·Mar 17, 2026 at 07:06 AM024960.00%
Wuhan YZY Biopharma Wins FDA IND Approval for Bispecific Antibody M701 in Malignant Pleural EffusionTip Ranks·Feb 3, 2026 at 10:40 AM024960.00%